Abstract | Discoveries made over the past 20 years highlight the importance of mRNA decay as a means of modulating gene expression and thereby protein production. Up until recently, studies largely focused on identifying cis-acting sequences that serve as mRNA stability or instability elements, the proteins that bind these elements, how the process of translation influences mRNA decay and the ribonucleases that catalyse decay. Now, current studies have begun to elucidate how the decay process is regulated. This Review examines our current understanding of how mammalian cell mRNA decay is controlled by different signalling pathways and lays out a framework for future research.
mRNAs largely exist to produce proteins. The amount of protein generated from any given mRNA depends not only on the rate of mRNA translation but also on the rates of mRNA synthesis and decay. Levels of mRNA are influenced by the efficiencies and nucleotide positions at which gene transcription, precursor mRNA (pre-mRNA) splicing, pre-mRNA 3′ end formation and other post-transcriptional modifications -such as A-to-I editing -occur, as well as by the efficiency of mRNA export from the nucleus to the cytoplasm. Remarkably, cytoplasmic mRNA decay can be affected by these same nuclear processes, which have the potential to alter mRNA metabolism by altering mRNA sequences and/or mRNA ribonucleoprotein (mRNP) composition, as well as the translational status of the mRNA 1 
.
Although this Review will focus on the regulation of mRNA decay in mammalian cells, the paradigms, if not the specifics, generally apply to other organisms. Decay of mRNA can be broadly divided into two classes: mechanisms of quality control that eliminate the production of potentially toxic proteins and mechanisms that lengthen or shorten mRNA half-life for the purpose of changing the abundance of functional proteins. The cytoplasmic decay machinery consists of five types of ribonucleolytic activities, the combinatorial and ordered use of which varies depending on the mRNA substrate and cellular conditions. These five activities mediate decapping, 5′-to-3′ exonucleolytic decay, deadenylation, 3′-to-5′ exonucleolytic decay or endonucleolytic cleavage [2] [3] [4] 
Each activity may gain access to an mRNA, depending on the proteins and also, possibly, on the antisense noncoding RNAs (ncRNAs) that are bound to the mRNA.
mRNA-associated proteins and ncRNAs can influence the rate of mRNA decay directly by promoting or precluding decay factor binding, indirectly by influencing the cellular location and/or translational status of the mRNA, or both. Constituents of mRNP provide a plethora of possible fates for an mRNA as they associate or dissociate from mRNA in response to cellular conditions -such as the cell cycle or external stimuli -and these conditions can also regulate the abundance, cellular location and activity of mRNP constituents. Thus, a complicated intracellular and intercellular network underlies regulation of cytoplasmic mRNA decay. Our current appreciation of this network is attributable to the development of methods for purifying and characterizing the constituents of mRNPs. For example, after immunoprecipitating a particular mRNA-binding protein, the associated proteins and their post-translational modifications can now be identified using mass spectrometry, and the associated transcripts can be identified using microarray analyses or, most recently, using deep sequencing. The localization of each protein and ncRNA to a particular mRNA sequence and/or mRNP subcomplex, together with experiments that assess the functional consequence of mRNA binding under different conditions, provide information that is essential for understanding mRNA metabolism, including understanding the control of mRNA half-life.
Currently, studies of the conditional regulation of mRNA decay represent only a small fraction of what is undoubtedly a vast and interconnected cellular repertoire. This Review highlights our current understanding of how the cytoplasmic decay of mammalian cell mRNAs is regulated, thereby establishing a base for future work. We begin with the regulation of nonsense-mediated mRNA decay (NMD), which, unlike most mRNA decay pathways, appears to be restricted to newly synthesized transcripts. We then discuss the regulation of histone mRNA decay to exemplify a cell-cycle-regulated process, Nonsense-mediated mRNA decay (NMD) . In mammalian cells, this pathway targets newly synthesized mRNAs undergoing a pioneer round of translation. It generally eliminates spliced mRNAs that prematurely terminate translation but also has some physiologic targets. It competes with STAU1-mediated mRNA decay.
Regulation of cytoplasmic mRNA decay
Daniel R. Schoenberg 1 and Lynne E. Maquat Exonuclease-mediated decay (panel a of the figure) begins with shortening of the poly(A) tail by the complex of PAB-specific ribonuclease 2 (PAN2) and PAN3, by a multisubunit deadenylating complex containing the CCR4-NOT transcription complex subunit 6 (CNOT6), CNOT6L, CNOT7 and/or CNOT8 or by the deadenylase poly(A) ribonuclease (PARN) (reviewed in REF.
2). The protein constituents of the mRNA ribonucleoprotein (mRNP) determine which deadenylase is selected, but the details of this process are poorly understood. Next, the Nudix domain proteins mRNA-decapping enzyme 2 (DCP2) or NUDT16 (also known as syndesmos) hydrolyse the cap, and the body of the mRNA is degraded with 5′-to-3′ polarity by 5′-to-3′ exoribonuclease 1 (XRN1) 3 and/or 3′-to-5′ polarity by the exosome-associated exonucleases RRP44 or exosome component 10 (EXOSC10; also known as PM/Scl-100) 100 . Decay 3′-to-5′ can occur without prior decapping 43 . For some mRNAs, decay is initiated by endonuclease cleavage within their body, followed by degradation of the upstream cleavage product by the exosome and degradation of the downstream cleavage product by XRN1 (reviewed in REF. 4 ; panel b of the figure). The mRNA degradative enzymes that are relevant to this Review, their activities and their substrates are listed in the table. Mammalian cells have two forms of RRP44: DIS3 and DIS3L. DIS3 has both endo-and exonuclease activity, but is restricted to the nucleus. DIS3L has only 3′-5′ exonuclease activity, and it is this form that functions in cytoplasmic mRNA decay. IRE1, inositol-requiring enzyme 1; NMD, nonsense-mediated mRNA decay; PMR1, polysomal ribonuclease 1; SMG6, suppressor of morphogenetic effect on genitalia 6.
AU-rich element (ARE)-mediated mRNA decay, which involves 3′ untranslated region (UTR) destabilizing elements, and mRNA decay in response to nuclear receptors. In addition, we examine how endonucleolytic mRNA decay activities are controlled. This Review illustrates ways in which mRNA decay endows cells with effective responses to changing milieus and provides some examples of how dysregulation of mRNA decay can have an impact on disease-associated processes.
Nonsense-mediated mRNA decay Because mRNAs primarily function as templates for protein synthesis, it is logical that cells have evolved translationdependent quality-control mechanisms to dispose of defective mRNAs that synthesize abnormal proteins.
NMD, which occurs in all eukaryotes that have been studied, eliminates mRNAs that prematurely terminate translation. This mechanism dampens the potentially toxic effects of defective transcripts that are routinely generated during gene expression 5 . Downregulating the essential NMD factor up-frameshift 1 (UPF1) using short interfering RNA (siRNA) upregulates ~5% of properly functioning transcripts 6 in HeLa cells. A similar percentage (~4%) is upregulated using siRNA targeting the UPF2 NMD factor 7 . Thus, a substantial number of physiologic cellular transcripts are likely either to be direct NMD targets or to be downregulated by a direct NMD target, suggesting that NMD functions in cellular processes in addition to quality control. The recent proposal that NMD targets are the primary source of No-go mRNA decay A pathway that degrades faulty mRNAs associated with stalled ribosomes. Decay is initiated by endonucleolytic cleavage near the stall site to release sequestered ribosomes and associated translation factors for the translation of other mRNAs.
Non-stop mRNA decay
A pathway that degrades mRNAs lacking a stop codon and, thus, direct translation either through the poly(A) tail owing to, for example, premature polyadenylation, or to an mRNA breakpoint. It facilitates the recycling of ribosomes and translation factors.
Exon junction complex
(EJC). A protein complex that is deposited ~20-24 nucleotides upstream of splicing-generated exon-exon junctions. It includes the nonsense-mediated mRNA decay factors UPF3X and UPF3 among many other factors.
Premature termination codon
(PTC). A stop codon that is positioned 5′ to the normal termination codon. It usually activates nonsense-mediated mRNA decay when situated >50 nucleotides upstream of a splicing-generated exon-exon junction.
SURF
A complex of SMG1, UPF1, eRF1 and eRF3 that recognizes a premature termination codon.
Mammalian target rapamycin complex 1 (mTORC1). This complex consists of the phosphatidylinositol 3 kinase (PIK)-related serine/threonine protein kinase mTOR, raptor and LST8. mTORC1 is inhibited by low nutrient levels, growth factor deprivation and other stresses so that cellular protein synthesis is concomitantly inhibited.
antigenic peptides for the major histocompatibility class I pathway, which presents endogenous cellular peptides to T cells 8 , provides another emerging role for NMD in humans and, most likely, in all mammals.
Besides NMD, other mammalian cell quality-control mechanisms consist of no-go mRNA decay and non-stop mRNA decay 9 . NMD is the best characterized of the three and is the only one that has been studied in detail from a regulatory perspective. Thus, we will restrict our qualitycontrol comments to NMD (see REFS 5, 10 for recent detailed reviews).
Targets of NMD.
NMD is one of a number of mammalian cell mRNA decay pathways that is coupled to the translation of its target. Therefore, regulators of translation must be considered to be regulators of NMD. Although they have been debated, data indicate that mammalian cell NMD largely, if not exclusively, degrades newly synthesized mRNAs. During what has been termed the 'pioneer round' of translation, these are bound at their 5′ caps by the cap-binding protein (CBP) complex (CBC) CBP80-CBP20, at their poly(A) tails by poly(A)-binding protein N1 (PABPN1) and PABPC1 and, if they are derived from pre-mRNA splicing, at exon-exon junctions by an exon junction complex (EJC) 5 . Notably, this 'round' can be associated with more than one ribosome, depending on the translation initiation efficiency and on the length of the reading frame. Mammalian cell NMD does not appear to target older mRNAs, which are more abundant and direct the bulk of cellular protein synthesis. Older mRNAs are bound at their caps and poly(A) tails by eukaryotic translation initiation factor 4E (eIF4E) and PABPC1, respectively, and they lack detectable EJCs even if they are derived from pre-mRNA splicing. For simplicity, here we refer to the new mRNAs as CBC-bound and to the older mRNAs as eIF4E-bound. It should be noted that NMD does not appear to be restricted to newly synthesized mRNAs in non-mammalian cells. In mammals, cap-bound CBP80 transiently and/or weakly interacts with a key NMD factor, UPF1, prior to the pioneer round of translation (FIG. 1) . This interaction promotes NMD if the mRNAs contains a translation termination codon -often a premature termination codon (PTC) -more than ~50-55 nucleotides upstream of an EJC-bound exon-exon junction 11 (FIG. 1) . The absence of CBP80 and EJCs on eIF4E-bound mRNAs at least in part explains the immunity of these mRNAs to NMD.
Inhibitors and activators of translation-dependent mRNA decay. NMD is inhibited by negative regulators of the pioneer round of translation, which sometimes also negatively regulate the translation of older mRNAs. For example, some stresses -such as amino acid starvation, viral infection, heat shock, oncogenic stress created by MYC overexpression and early stages of hypoxiainhibit the translation of both CBC-bound mRNAs and eIF4E-bound mRNAs 12, 13 . These stresses trigger a signalling cascade that results in the phosphorylation of the translation initiation factor eIF2α and/or the proteolysis of translation initiation factors that are required for both types of translation (FIG. 2) . In the case of the early stages of hypoxia, inhibition of both forms of translation involves inhibition of the mammalian target of rapamycin complex 1 (mTORC1) 14 . Inhibition of translation of CBC-bound mRNAs (and hence of NMD) only occurs during the early stages of hypoxia, whereas inhibition of translation of eIF4E-bound mRNAs persists during hypoxia. This may be beneficial because several mRNAs that contribute to the cellular response to stress are NMD targets 15 . For example, activating transcription factor 4 (ATF4) mRNA is an NMD target, and ATF4 triggers transcription of some proteins that are toxic in unstressed cells.
NMD is activated by positive regulators of the pioneer round of translation. CBC-bound mRNA translation, like eIF4E-bound mRNA translation, is activated via the mTOR pathway, although it is done so by a mechanism that involves the EJC constituent S6K1 ALY-REFlike target (SKAR; also known as POLDIP3), which is Gppp cap by cap-binding protein 80 (CBP80) and CBP20. A | NMD is triggered by a weak and/or transient interaction of up-frameshift 1 (UPF1) with cap-bound CBP80. Notably, this action typifies all newly synthesized mRNAs 11 . Next, the suppressor of morphogenetic effect on genitalia 1 (SMG1) -which is a phosphatidylinositol 3 kinase (PIK)-related serine/ threonine protein kinase that phosphorylates multiple residues in the carboxy-terminal region of UPF1 (REF. 25 ) -binds together with UPF1 to the two translation termination factors, eukaryotic release factor 1 (eRF1) and eRF3, to form SURF at a premature termination codon (PTC). B | During the formation of the SURF complex, SMG1 kinase activity is suppressed by SMG8 by formation of the so-called SMG1 complex (SMG1C) 113 . Following this, SMG1-UPF1 is joined to an exon junction complex (EJC) that resides downstream of the PTC 11 . C | This is dependent upon UPF3X out-competing its functionally less-effective paralogue UPF3 for binding at the EJC 27 . D | The SMG1-mediated phosphorylation of UPF1 that then occurs is a consequence of SMG1-UPF1 binding directly to the UPF2 EJC constituent. Phosphorylated UPF1 binds to eIF3, should a pre-initiation complex form at the AUG translation initiation codon, inhibiting additional rounds of translation initiation 23 . E | SMG6 then binds UPF1 dependent on the phosphorylation of UPF1 at threonine 28, and SMG5 and SMG7 bind UPF1 following its phosphorylation at serine 1,096 (REF. 24 ). It is unclear when the 43S pre-initiation complex is lost. F | The SMG5-and SMG7-mediated decay of the NMD target occurs by decapping and/or deadenylation (a) followed by degradation of the body of the transcript in the 5′-to-3′ direction from the decapped 5′ end and/or 3′-to-5′ direction from the 3′-deadenylated end 114 (b). G | A parallel pathway (a) involves the SMG6-mediated endonucleolytic cleavage of the NMD target and the accompanying rapid decay of the resulting 5′ cleavage product and 3′ cleavage product (b) 115, 116 . Decay of the 3′ cleavage product requires mRNA ribonucleoprotein (mRNP) disassembly that is mediated by UPF1 (REF. 118 . Translational activation, and thus the activation of any associated mRNA decay pathways, involves mTOR complex 1 (mTORC1) binding to eIF3, which results in the phosphorylation of the eIF4E-binding protein 1 (4EBP1) translational repressor and consequently in the dissociation of inactivated 4EBP1 from mRNA-bound eIF4E. eIF4G can then interact with and stabilize the binding of eIF4E, eIF4A and poly(A)-binding protein C1 (PABPC1) to mRNA to ensure efficient translation. mTORC1 binding to eIF3 also results in the phosphorylation of the S6 kinase 1 (S6K1) translational activator and consequently the dissociation of activated S6K1 from mRNA-bound eIF3. Dissociated S6K1 phosphorylates eIF4B and tumour suppressor programmed cell death 4 (PDCD4), which augment scanning of the 43S pre-initiation complex to the translation initiation codon. b | The pioneer round of translation uses newly synthesized mRNA that is bound by the cap-binding protein (CBP) heterodimer CBP80-CBP20 (called the cap-binding complex (CBC)) and, providing that the mRNA has been derived from splicing, at least one exon junction complex (EJC; this consists of but is not limited to MAGOH, Y14, PYM and eIF4AIII) situated ~20-24 nucleotides upstream of such a junction. This round of translation (and, thus, NMD for those mRNAs that are NMD targets) is promoted following activation of the mTORC signalling pathway -that is, in the absence of stress and the presence of growth factors -by multiple pathways. Taking cues from how mTOR activates eIF4E-bound mRNA translation, the mTOR-mediated translational activation of CBC-bound mRNA -and thus the activation of NMD -may also involve mTORC1 binding to eIF3 and the dissociation of activated S6K1 from CBC-bound mRNA. Activated S6K1 is then recruited by the EJC constituent S6K1 ALY-REF-like target (SKAR), which promotes the pioneer round of translation by enhancing the phosphorylation of SKAR and of other downstream effectors that may include eIF4B and PDCD4, which associate not only with eIF4E-bound mRNA but also with CBC-bound mRNA 119 . Occurring in parallel, S6K1 phosphorylation by the CDC42 kinase may augment binding of the CBC to mRNA caps, serine/arginine-rich splicing factor 1 (SRSF1) may initiate S6K1 signalling via mTORC1, and the interaction of protein PYM with the EJC core proteins Y14 and eIF4AIII and the 40S ribosomal subunit all appear to promote the pioneer round of translation and, when appropriate, NMD. This figure is modified, with permission, from the original in REF. 5 © (2010) Cell Press.
Box 2 | STAU1-mediated mRNA decay STAU1-mediated mRNA decay (SMD) targets mRNAs that contain a 3′ untranslated region (UTR) STAU1-binding site (SBS), providing that translation terminates sufficiently upstream of the SBS 101 . After translation termination, usually at the normal termination codon, the direct interaction of SBS-bound STAU1 with the key nonsense-mediated mRNA decay (NMD) factor up-frameshift 1 (UPF1) results in UPF1 phosphorylation and SMD. This series of events appears to be analogous to what occurs during NMD: when translation terminates sufficiently upstream of an exon junction complex (EJC), usually at a premature termination codon, the direct interaction of the EJC with UPF1 triggers UPF1 phosphorylation and NMD. It seems reasonable to think that the SMD and NMD pathways converge following UPF1 phosphorylation. However, unlike NMD, SMD occurs independently of cap-binding protein 80 (CBP80) and EJCs and targets not only newly synthesized CBC-bound mRNAs but also older eIF4E-bound mRNAs 102 . Cell-cycle-regulated histone mRNA decay is also likely to occur during both pioneer and subsequent rounds of translation, as stemloop-binding protein (SLBP) is required for histone mRNA 3′ end formation within nuclei 103 and thus probably binds not only eIF4E-bound but also CBC-bound histone mRNA.
STAU1-mediated mRNA decay
(SMD). A pathway that degrades mRNAs that harbour a STAU1-binding site within their 3′ untranslated region. It depends on translation and on the nonsense-mediated mRNA factor UPF1.
detected on CBC-bound but not on eIF4E-bound mRNA (FIG. 2) . Additional proteins that promote the translation of CBC-bound mRNA and that are absent from eIF4E-bound mRNA include other EJC constituents 16 (such as Y14 and PYM 17 ) and serine/arginine-rich splicing factor 1 (SRSF1; also known as SF2 or ASF1). SRSF1 recruits mTOR and another translational activator, TAP (also known as NXF1) 18, 19 (FIG. 2) . The finding that SKAR augments cell size and thus presumably global protein synthesis 20 is reminiscent of data indicating that PYM or SRSF1 somehow likewise increases mRNA translation beyond the pioneer round of translation.
NMD factors as regulators of NMD. NMD can be regulated at the level of individual NMD factors or in feedback loops that coordinately control the abundance of one or more different NMD factors. The steps of the mammalian NMD pathway are shown in FIG. 1 (however, there is an alternative, less well-understood pathway of NMD as well 21, 22 ). Phosphorylation of NMD factors is an important mode of regulation of their activity and thus of NMD; some key examples are noted here. The phosphorylation of UPF1 by a phosphatidylinositol kinase (PIK)-related serine/threonine protein kinase called suppressor of morphogenetic effect on genitalia 1 (SMG1) is triggered when both UPF1 and SMG1 interact with a downstream EJC 11 (FIG. 1A) . The phosphorylated form of UPF1 prevents additional rounds of translation initiation on the NMD target 23 (FIG. 1D) .
SMG5-SMG7 or SMG6 at some point bind to phosphorylated UPF1 (REF. 24) (FIG. 1E) , resulting in exonucleolytic degradation (FIG. 1Fa,b) or endonucleolytic cleavage (FIG. 1Ga,b) , respectively. SMG5-SMG7 and/or SMG6 also promote dephosphorylation of UPF1 by protein phosphatase 2A (PP2A), which enables UPF1 recycling 25, 26 . It is uncertain whether this occurs on the NMD target and in a way that is essential for the decay of that target or whether it occurs after UPF1 is released from the NMD target 23, 24, 26 . The abundance of NMD factors can also be regulated. Arguably, the best characterized example of this is the interplay between UPF3 (also called UPF3A) and UPF3X (also called UPF3B). UPF3X has a higher affinity for the EJC than its paralogue UPF3 does, and the failure of UPF3 to compete effectively with UPF3X for EJC binding results in UPF3 destabilization 27 (FIG. 1B) .
Feedback loops also coordinately regulate the level of NMD factors 28, 29 . A multipronged negative feedback regulatory network acts on the seven NMD factorsnamely, UPF1, UPF3X, UPF2, SMG1, SMG5, SMG6 and SMG7 -that are rate-limiting to NMD in HeLa cells; this feedback network buffers the cells from perturbations and maintains homeostasis 29 . The HeLa cell mRNAs that encode these factors are regulated by different UPF1-dependent branches of NMD: UPF1 and SMG5 mRNAs are upregulated following depletion of the eIF4AIII EJC constituent; SMG1 mRNA is selectively upregulated following depletion of the EJC constituent RNPS1; and UPF1 and SMG7 mRNAs are selectively upregulated following downregulation of either or both UPF3 or UPF3X 29 . This intricate network is not limited to HeLa cells (see below) or even to mammalian cells, and it appears to minimize side effects when NMD is perturbed by a change in the level of one or more NMD factors.
The efficiency of NMD is also affected by microRNAs (miRNAs). For example, the efficiency of NMD for mRNAs that bind the miRNA-induced silencing complex appears to be reduced owing to miRNA-mediated translational repression of CBC-bound mRNA 30 . Of course, miRNAs that target one or more NMD factors would also influence the efficiency of NMD (see below).
NMD cell-and tissue-specific differences. Variations in the efficiency of NMD are evident when comparing different cell lines or different tissues 31 . For example, the efficiency of NMD decreases during the differentiation of mouse C2C12 myoblasts to myotubes. During differentiation, the abundance of the NMD factor UPF2 decreases more than the abundance of STAU1, which functions during STAU1-mediated mRNA decay (SMD)
. STAU1 thus competes more effectively than UPF2 for binding to UPF1 (REF. 32 ). The cause of the changes in UPF1 and STAU1 abundance during myogenesis has yet to be determined. As another example, the efficiency of NMD in the brain is decreased by miRNA-128, which targets UPF1 and the EJC core constituent metastatic lymph node gene 51 (MLN51; also known as CASC3), and miR-128 levels increase during brain development and in differentiating neuronal cells 33 . Intrinsic differences among cell types in the specific negative regulatory feedback mechanisms that are active also exist depending on which NMD factor (or factors) happens to be rate-limiting 29 . For example, in contrast to UPF3X-deficient HeLa cells that expressed elevated levels of UPF1 and SMG7 mRNAs, lymphoblastoid cells from patients with UPF3X deficiency had upregulated levels of not only UPF1 and SMG7 mRNAs but also of UPF2 mRNA relative to control lymphoblastoid cells.
Differences in the efficiency of NMD also occur in a developmentally controlled fashion, the molecular basis of which may reflect the relative abundance of NMD factors or the ability of a particular newly synthesized mRNA to undergo the pioneer round of translation 34 . In the case of the latter, mRNAs may be sequestered into translationally inactive particles until they are properly localized in time and in space.
Histone mRNA decay
The decay of histone mRNAs in metazoans provides a particular example of cell-cycle-restricted expression mediated by the regulation of mRNA degradation. The half-life of such histone mRNAs decreases from between 45 and 60 minutes during S phase to 10 minutes at the end of S phase. This decrease has a major role in coordinating histone protein synthesis with DNA replication. Although histones are required for packaging newly replicated DNA during S phase, histone mRNA transcription continues beyond S phase, albeit at a reduced rate. Cell-cycle-regulated histone mRNAs are exceptional because they lack a poly(A) tail and instead end in a conserved stem-loop structure that binds stem-loop-binding protein (SLBP), which is only present during S phase and is crucial for efficient histone mRNA 3′ end formation in the nucleus and for efficient histone mRNA translation in the cytoplasm 35 . At the end of S phase, when histone mRNA terminates translation, SLBP that is bound to the histone mRNA stem-loop recruits the NMD factor UPF1 (REF. 36 ) (presumably analogously to how STAU1 that is bound to a STAU1-binding site recruits UPF1 when translation terminates normally on a target of SMD) so as to trigger mRNA decay. Whereas UPF2 and UPF3 do not function in either histone mRNA decay or in SMD, SMG1 does, presumably by phosphorylating UPF1 (W. F. Marzluff, personal communication; L.E.M., unpublished data).
Regulated histone mRNA decay also requires the PIK-related protein kinase ataxia telangiectasia-mutated and Rad 3-related (ATR) 36 , which is a checkpoint kinase that is active during normal S phase progression and properly schedules the initiation of DNA replication. ATR mediates the decay of histone mRNA in a manner that is independent of its role in DNA synthesis. However, the ATR target (or targets) that functions in degrading histone mRNA remains unknown. Regulated histone mRNA decay additionally requires the cellcycle-regulated protein complex cyclin A2-CDK1 and casein kinase 2 (CK2), which phosphorylate SLBP at the end of S phase, thus triggering SLBP degradation by an undefined ubiquitin ligase 37, 38 .
Another example of cell-cycle-regulated mRNA degradation may be found in the degradation of mRNA for the cell cycle regulator cyclin B by an RNase called mitochondrial RNA processing (MRP). Mutated variants of MRP in patients with cartilage hair hypoplasia result in an increase in the level of cyclin B mRNA (reviewed in REF. 39 ). In yeast, downregulation of cyclin B is known to be regulated by MRP.
ARE-mediated mRNA decay AU-rich elements. AU-rich elements (AREs) are the largest and most studied group of cis-acting mRNA instability determinants. The canonical AREs generally have one or more copies of the AUUUA pentamer that are usually embedded in a U-rich context. If they are classified by sequence alone, canonical ARE-containing mRNAs constitute up to 9% of cellular mRNAs 40 . AREs have been grouped into three broad categories based on the number and context of the AUUUA repeats 41 . The decay of ARE-containing mRNAs begins with either synchronous or distributive poly(A) shortening 42 , and the subsequent steps target the body of the mRNA from both ends (BOX 1a) via the actions of the 5′-to-3′ and 3′-to-5′ exonucleases 43 . There are other cis-acting instability elements, the most studied of which are the GU-rich elements (GREs) 44 . GREs function in post-transcriptional regulons that control pre-mRNA splicing and/or mRNA decay and that are coordinated by binding of the CUGBP Elav-like family (CELF) proteins, the best known of which is CELF1 (also called CUGBP1) 45, 46 . Less is known about the regulation of GRE-mediated mRNA decay, and the reader is directed to a recent review 47 . AREs are found in the tightly regulated mRNAs that encode proto-oncogene proteins (for example, c-FOS) and inflammatory mediators (for example, tumour necrosis factor-α (TNFα), interleukin 1 (IL-1), IL-2, IL-3 and granulocyte macrophage colony-stimulating factor (GMCSF)). Together with ARE-binding proteins (ARE-BPs), AREs have important physiological and pathological functions, not all of which are the result of triggering rapid mRNA turnover [48] [49] [50] [51] [52] . The inflammatory response provides a good example of the physiological and pathological ramifications of ARE-mediated mRNA decay. The cytokines and chemokines that are elaborated by macrophages and monocytes after injury neutralize the damaging agent and repair damaged tissue; however, these proteins can also harm healthy tissue, and conditions that interfere with the destabilization of the mRNAs that encode pro-inflammatory proteins contribute to atherosclerosis, rheumatoid arthritis and asthma 53 . The complexity of the ARE mRNA transcriptome is seen in the changing steady-state levels of AREcontaining mRNAs subsequent to the treatment of resting human T cells with antibodies that bind T cell receptors and that stimulate proliferation and changes in gene expression 54 . Out of 900 ARE-containing mRNAs that were assayed using microarrays, the steady-state levels of 250 declined within 30 minutes of stimulation. mRNAs in this group encode regulators of quiescence, such as phosphatase and tensin (PTEN), inositol trisphosphate 3 kinase B (ITPKB) and calcineurin A, suggesting Alternative cleavage and polyadenylation (APA). Provides a means to vary mRNA 3′ end formation and, thus, the regulatory sequences often present within 3′ untranslated region sequences.
Mitogen-activated protein kinase
(MAPK). Proteins of this sort function in signal transduction by amplifying and integrating signals from different receptors followed by delivering each signal to one or more endpoint effector proteins.
14-3-3 adaptor proteins
A group of seven ubiquitously expressed phosphoserine/ phosphothreonine-binding proteins. They can assemble into homo-or heterodimers, mediate protein-protein interactions and function in many cellular processes.
that the decay of these ARE-containing mRNAs has a role in the signal-transduction-mediated transition from quiescence to proliferation. It is not clear from this or from many other studies why, under different conditions, some mRNAs with one or more AREs undergo accelerated decay and others do not. This may result from constraints imposed by sequence context, secondary structure and binding of proteins and/or ncRNAs at adjacent or overlapping sites (see below). Furthermore, not all ARE-BPs confer mRNA instability (see below). As noted, widespread alternative 3′ end processing 55 complicates the challenge of identifying mRNAs that contain functional AREs
ARE-BPs. ARE-BPs can be grouped by their stabilizing or destabilizing effects on the mRNA, by their type of RNA-binding motif and by the proteins that modify their action, and some of the better studied ARE-BPs are listed in BOX 4a. ARE-BPs can be regulated by kinases, phosphatases and, at least in one case, by an arginine methyltransferase. As a general rule, ARE-BPs function as multimers and can be phosphorylated at the same site by different kinases or at different sites by different kinases.
Phosphorylation regulates cytoplasmic ARE-BP function. For simplicity, the rapid degradation of AREcontaining mRNAs can be thought of as a default process, and the destabilizing proteins tristetrapolin (TTP), butyrate response factor 1 (BRF1; also known as TF3B90), BRF2, KH-type splicing regulatory protein (KSRP; also known as FUBP2) and some forms of AUF1 (also known as hnRNPD) function to recruit one or more of the degradative enzymes shown in BOX 1 to mRNPs 56 . When it is considered in this way, stabilization results from: the dissociation of a destabilizing ARE-BP; interference of the interaction between a destabilizing ARE-BP and one or more ribonucleases; and/or replacement of a destabilizing ARE-BP by a stabilizing ARE-BP.
Phosphorylation regulates the binding and function of ARE-BPs. The p38 mitogen-activated protein kinase (MAPK), MAPK-activated protein kinase 2 (MK2) and the nonspecific serine/threonine protein AKT kinase pathways each have major roles in regulating the binding and activity of ARE-BPs by phosphorylation (BOX 4b) . Of these proteins, TTP is the best studied with regard to upstream signalling processes, and the interplay of kinases and phosphatases in the regulation of its destabilizing activity is shown in BOX 4. In mammals, p38 MAPK is activated by stress or by inflammatory stimuli: for example, by treating macrophages with bacterial lipopolysaccharide (LPS). p38 MAPK then phosphorylates MK2, which activates MK2 phosphorylation of TTP 57, 58 . TTP is phosphorylated at multiple sites, and the subsequent binding of one or more of the 14-3-3 adaptor proteins 59, 60 interferes with the TTP-mediated recruitment of deadenylases that are required to initiate mRNA decay 61, 62 . Similar results were reported for BRF1 (REF. 63 ), which is phosphorylated by AKT in response to activation of an upstream PI3 kinase (PI3K) pathway 64, 65 . Note that AKT can also be activated by MK2, and constitutively active AKT is a common feature of many cancers.
KSRP, which acts like TTP and BRF1 by recruiting one or more degradative enzymes to ARE-containing mRNPs, is also regulated by phosphorylation, albeit directly by p38 MAPK 66 . However, phosphorylation reduces KSRP binding to RNA without altering its interaction with the exosome or the poly(A) ribonuclease PARN 67 . Although AUF1 can be phosphorylated in vitro by protein kinase A (PKA) and glycogen synthase kinase 3β (GSK3β) 68 , only the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) tyrosine kinase has been shown in vivo to stabilize ARE-containing mRNAs that are targeted by AUF1 (REF. 69 ). NPM-ALK is a constitutively active kinase that is expressed in anaplastic large-cell lymphoma as a result of the fusion between the genes for NPM and ALK owing to a chromosomal translocation. Although as of yet unproven, the stabilization of ARE-containing mRNAs by the NPM-ALK-mediated phosphorylation of AUF1 may play a part in promoting malignant transformation.
The ARE-BP HuR (also known as ELAVL1) counteracts the destabilizing effects of TTP, BRF1, KSRP and AUF1 (BOX 4b) . Although HuR is primarily regulated at the level of nucleocytoplasmic shuttling (see below), its ARE-binding affinity is also both positively and negatively regulated by phosphorylation. An example of this is its stress-induced phosphorylation (for example, after ionizing radiation) by the checkpoint homologue kinase 2 (CHK2). HuR is phosphorylated at the same sites by PKCγ and, as described above, directly by p38 MAPK (see REF. 48 for a detailed review).
The role of phosphatases in regulating AREmediated mRNA decay is less well-studied. The destabilizing activity of TTP is increased by PP2A acting directly to remove the inactivating phosphates from the protein 70 , but the signalling process and mechanism of this targeting are currently unknown. The phosphorylation state of TTP is further reduced by PP2A
Box 3 | Regulation of mRNA decay by alternative 3′ end formation
Cleavage and polyadenylation sites exist to form the 3′ ends of precursor mRNAs (pre-mRNAs) and, thus, the mRNAs that derive from them. Almost all human pre-mRNAs possess multiple cleavage and polyadenylation signals in their 3′ untranslated regions (UTRs), and the analysis of expressed sequence tags indicates that about half of pre-mRNAs use alternative cleavage and polyadenylation (APA) sites 104, 105 . As most cis-acting elements that regulate mRNA half-life are situated within 3′UTRs, mRNAs containing shorter 3′UTRs have often lost one or more regulatory pathways that are dictated by, for example, microRNA-binding sites and thus have greater stability 55 . APA can be regulated by changes in the abundance of one of the ~90 proteins involved in 3′ end maturation and/or a number of signal transduction pathways. For example, in day-18 embryonic rats, the use of APA sites is activated for ~10% of transcripts that are upregulated by the transcriptional activator myocyte enhancer factor 2 (MEF2) in response to extracellular signalling that increases synaptic activity in hippocampal neurons 106 . As another example, in response to oxidative stress, CKIα -which is sensitive to the lipid messengers PI4, 5P 2 and CKIε -phosphorylates and thereby upregulates the activity of the non-canonical nuclear poly(A) polymerase (PAP) called Speckel-targeted phosphatidylinositol-4-phosphate 5-kinase Iα-regulated (STAR)-PAP so as to enhance STAR-PAP cleavage and polyadenylation on select target pre-mRNAs 107 . Nature Reviews | Genetics 
to the mRNA, and stabilization results from interference with this process. ARE-containing mRNAs are stabilized by mitogen-activated protein kinase (MAPK)-activated protein kinase 2 (MK2)-mediated phosphorylation of tristetraprolin (TTP) and butyrate response factor 1 (BRF1) 58, 63 , by p38 MAPK phosphorylation of KH-type splicing regulatory protein (KSRP) 66 , by AKT-mediated phosphorylation of BRF1 and KSRP 64 and by NPM-ALK-mediated phosphorylation of AUF1 (REF. 69 ). By contrast, the destabilizing activity of TTP is increased following phosphorylation by protein kinase C (PKC). Each of these kinases is activated by upstream signalling processes, such as the p38 MAPK-MK2 pathway shown here. The phosphatases MKP1 and protein phosphatase 2A (PP2A) exert stabilizing effects on ARE-containing mRNAs by dephosphorylating the upstream kinases (for example, p38 MAPK and MK2; see panel a of the figure) 71 . HuR (shown in purple) has an overall stabilizing effect on ARE-containing mRNA, and its binding is regulated both positively (for example, by PKC and p38 MAPK) and negatively (for example, by CDK1 and CHK2) by phosphorylation (reviewed in REF. 48 ). The destabilizing activity of TTP has been studied in detail (panel b of the figure, reviewed in REF. 108 ). Non-phosphorylated TTP that is bound to the ARE recruits deadenylases to activate the decay process. This is inhibited by the phosphorylation of TTP at multiple sites by MK2, which functions downstream of activated p38 MAPK 57, 58 . Stabilization of mRNA results from the binding of 14-3-3 proteins to phosphorylated TTP 59, 60 , which blocks the interaction of TTP with the deadenylases 61, 62 . This process is reversed by removal of the inactivating phosphates by MKP1 or PP2A 70 , rendering the ARE-containing mRNA unstable. CARM1, coactivator-associated arginine methyltransferase 1; GRα, glucocorticoid receptor-α; RRM, RNA recognition motif.
acting upstream to dephosphorylate and thus to reduce the activity of the p38 MAPK and MK2 kinases. p38 MAPK and MK2 are also targets of MAP kinase phosphatase 1 (MKP1), the activity of which is stimulated by CK2 (REFS 67, 71) .
Regulation of cytoplasmic ARE-BP function by nuclear export. The nucleocytoplasmic distribution of ARE-BPs is a major regulatory nexus, and phosphorylation has different effects on TTP, AUF1 and HuR. For example, the export of TTP from the nucleus to the cytoplasm Photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP). A method for profiling RNA that is bound to a specific protein. Cells are grown in a medium containing 4-thiouridine or 6-thioguanosine, which, when it is incorporated into RNA, allows for efficient ultraviolet crosslinking to RNA-binding proteins. The immunoprecipitated protein-RNA complexes are then used to generate libraries for deep sequencing.
RNA-binding protein immunoprecipitation (RIP). A method for recovering
RNAs by virtue of their binding by a particular protein. This uses either an antibody specific to a particular RNA-binding protein or antibody to an epitope tag on a recombinant protein expressed in target cells.
depends on its phosphorylation in the nucleus by MK2 (REF. 72 ), and the binding of different 14-3-3 proteins distinguishes the export process from phosphorylationdependent changes in activity. The converse is true for AUF1, the dephosphorylation of which by MKP1 promotes its redistribution to the cytoplasm 73 . Phosphorylation at different sites on HuR controls the subcellular distribution of HuR, and its distribution between the nucleus and cytoplasm varies with the stage of the cell cycle. The cyclin mRNAs are among those in which stability is regulated by HuR, and HuR is retained in the nucleus at late G2 by CDK1 phosphorylation of residues within the HuR nucleocytoplasmic shuttling (HNS) motif 74 . Phosphorylation at other sites can have the converse effect, and the amount of cytoplasmic HuR is increased following phosphorylation by PKCα in response to activation of the G-protein-coupled purinergic P2Y2 receptor 75 , by PKCγ in response to angiotensin binding to its G-protein-coupled receptor 76 and by p38 MAPK 77 . The cytoplasmic accumulation of HuR can also be increased by methylation within the HNS: for example, by coactivator-associated arginine methyltransferase 1 (CARM1) in LPS-treated macrophages 78 .
Targets of HuR.
A recent study using photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP) to identify HuR-binding sites within the human embryonic kidney cell transcriptome identified 137,305 clusters, 106,840 of which mapped to protein-coding genes 79 . The degree of HuR binding was directly related to the degree of mRNA stabilization, and mRNA stabilization was greater for transcripts with both intronic and 3′UTR HuR-binding sites compared to transcripts with either site alone. This finding suggests some as of yet unknown link between nuclear premRNA processing and stability of these mRNAs in the cytoplasm. The proximity of HuR and miRNA-binding sites adds a layer of regulatory complexity to AREmediated mRNA decay and may explain how the stressinduced redistribution of HuR overcomes a specific case of miRNA-mediated silencing (namely, miR-122 targeting high-affinity cationic amino acid transporter 1 (CAT1) mRNA) 80 . As the PAR-CLIP results derive from normally cycling cells, they provide a general picture of the scope of HuR binding. The influences of stress, hormones or neurotransmitter signalling that change the intracellular distribution of HuR and its affinity for its target mRNAs will undoubtedly further enrich these regulatory processes.
Nuclear receptors can activate mRNA decay Nuclear receptors are ligand-dependent transcription factors that are responsible for activating or repressing gene expression in response to a range of molecules, including vitamin D and steroid or thyroid hormones among others. Depending on the type, the nuclear receptors are constitutively located in the nucleus or are in equilibrium between the cytoplasm and the nucleus when not bound by their ligand. After they have been bound to their respective ligands, these proteins undergo conformational changes and concentrate in the nucleus, where they interact with transcriptional coactivators or corepressors.
Nuclear receptors also have an impact on posttranscriptional processes, and the glucocorticoid receptor is one of the few that has been studied in detail. Corticosteroids are used clinically to treat inflammation, and some of their anti-inflammatory effects result from changes in gene expression that indirectly impact AREmediated mRNA decay. For example, corticosteroids acting through the glucocorticoid receptor suppress the transcription of the p38 MAPK1 gene 81 and induce the transcription of the MKP1 (REF. 82) and TTP genes 82, 83 . However, the glucocorticoid receptor can also bind directly to some mRNAs and activate their decay 84, 85 . This was initially observed in airway epithelial cells and arterial smooth muscle cells for the mRNAs encoding the inflammatory chemokines CCL2 and CCL7 (REFS 84, 85) . RNA-binding protein immunoprecipitation (RIP) followed by microarray (RIP-chip) identified an additional ~500 mRNAs that are bound by the glucocorticoid receptor in vivo 84 . A consensus-binding motif was identified, but it remains to be determined how glucocorticoid receptor binding occurs and activates mRNA decay. Furthermore, it is not known whether ligand-dependent mRNA binding and destabilization is unique to the glucocorticoid receptor or whether it is also a property of other nuclear receptors.
Regulation of mRNA degradative activities
Remarkably little is known about how ribonucleases (BOX 1) are themselves regulated. Here we discuss endonucleases because, to date, there are no examples of direct regulation of any of the other mRNA degradative enzymes. It is not clear whether this is because no-one has looked for exonuclease regulation or whether most exonucleases are regulated through the proteins with which they interact.
Signalling processes activate PMR1-mediated mRNA decay. Polysomal ribonuclease 1 (PMR1) is one of five endonucleases that have been definitively shown to function in mRNA decay. PMR1-mediated mRNA decay depends on the ability of PMR1 to associate with polysome-bound substrate mRNA 86 . Binding of PMR1 to polysomes requires phosphorylation by the protooncogene tyrosine protein kinase SRC of the PMR1 carboxy-terminal domain 87, 88 to generate a binding site for an SH2 domain protein on the translating mRNP. In the one case studied, SRC is stimulated by epidermal growth factor (EGF) 88 , but it is likely that PMR1 phosphorylation is also regulated by other upstream activators of SRC. To date, the activation of PMR1 by SRC and of AUF1 by NPM-ALK (see above) provides the only examples of mRNA decay being regulated by oncogenic tyrosine kinases. The activity of polysome-bound PMR1 is further increased when oestrogen-responsive cells are exposed to oestrogen, but the mechanism for this is not known. PMR1 also binds to the cytoskeleton-regulatory proteins MENA and vasodilator-stimulated phosphoprotein (VASP), and these associations localize PMR1 to the
Stress granules
Large cytoplasmic foci containing non-translating mRNAs bound by the 40S ribosomal subunit. They accumulate in stressed cells, commonly as a result of translation inhibition that is secondary to the phosphorylation of eIF2α.
P bodies
Processing bodies, or P bodies, are small cytoplasmic RNA granules that are enriched for decapping proteins, activators of decapping, XRN1 and non-translating mRNAs. P bodies function as sites for mRNA storage and possibly decay.
Toll-like receptors
Single-chain, membrane-bound receptors that function in the innate immune response. Binding of bacterial cell wall components, such as lipopolysaccharides or lipomannins, activates binding of adaptor proteins that leads to the activation of NFκB and associated changes in transcription.
leading edge of motile cells, where it stimulates cell motility 89 . This effect is likely to be the result of localized mRNA decay.
IRE1 autophosphorylation and the unfolded-protein response. The unfolded protein response (UPR) is activated by the accumulation of misfolded or unfolded proteins in the endoplasmic reticulum. Its major function is to restore balance within the endoplasmic reticulum, although it induces apoptosis under conditions of prolonged or chronic stress. Inositol-requiring enzyme 1 (IRE1) functions as the principal sensor of unfolded proteins and is the primary effector of the UPR. Its oligomerization during the UPR results in autophosphorylation and activation of the cytoplasmic IRE1 endonuclease domain 90 . The amino-terminal sensor domain of IRE1, which is situated within the endoplasmic reticulum lumen, is normally bound by the HSP70 chaperone-binding immunoglobulin protein (BIP; also known as GRP78), and its displacement by unfolded proteins is one model for the subsequent oligomerization and activation of IRE1. The endonuclease activity participates in the non-canonical splicing of the mRNA that encodes the transcription factor X-box-binding protein 1 (XBP1), which positively regulates BIP expression levels. IRE1 also cleaves and destabilizes mRNAs encoding some of the proteins that transit through the endoplasmic reticulum (that is, membranebound and secreted proteins) 91, 92 in a process termed rapid IRE1-dependent decay (RIDD). Together with increased BIP levels, RIDD restores balance within the endoplasmic reticulum by reducing the amount of protein entering the secretory pathway. Because IRE1 substrate selectivity is determined by an N-terminal signal sequence that causes mRNAs that are associated with nascent peptides bearing this signal to be localized to the endoplasmic reticulum, RIDD is likely to be regulated by signalling that influences translation initiation.
The selective loss of endoplasmic-reticulum-associated mRNAs by RIDD contrasts with the generalized stabilization of the mRNA transcriptome that occurs during oxidative stress or amino acid starvation 93 . Stress-induced stabilization is particularly evident for ARE-containing mRNAs, where the accumulation of HuR in stress granules and P bodies is proposed to protect these transcripts by displacing destabilizing ARE-BPs 49 . It remains to be determined whether IRE1 only acts on endoplasmic-reticulum-associated mRNAs or whether RIDD can be activated independently of the UPR.
Induction of ZC3H12A by Toll-like receptor signalling. ZC3H12A (also known as MCPIP1) is the only example so far of an mRNA endonuclease that is transcriptionally induced 94, 95 . There is normally little ZC3H12A in cells. ZC3H12A synthesis is induced as part of the response by macrophages and monocytes to the binding of microbial cell wall components to Toll-like receptors. Zc3h12a -/-mice that have been treated with bacterial LPS overexpress IL-1, IL-6, TNFα and other cytokines as a consequence of failing to degrade the corresponding lymphokine mRNAs, resulting in a runaway inflammatory response. Unlike PMR1 and IRE1, which do not bind directly to their substrate mRNAs, ZC3H12A binds to its targets through a CCCH zinc finger that is similar to that of TTP and BRF1 (REF. 95 ). Although most ZC3H12A targets contain a 3′UTR ARE, sensitivity to ZC3H12A is imparted by a stem-loop structure that lies upstream of the ARE 94, 96 . ZC3H12A cleaves within this loop to initiate decay.
ZC3H12A is also able to cleave within the loop structures of pre-miRNAs during miRNA processing, where it acts in opposition to Dicer 97 . This has potential clinical relevance because elevated ZC3H12A expression is linked to the reduced expression of some miRNAs in lung cancer 97 . There is also emerging evidence that much of the mRNA transcriptome is subject to endonucleolytic cleavage 98 , thus extending the action of endonucleases beyond the initiation of mRNA decay.
Conclusions
It is clear that the field of mRNA decay is approaching the end of its beginning. Tremendous progress has been made towards understanding mRNA sequences that regulate mRNA stability and the enzymatic activities that mediate mRNA decay. The few examples provided in this Review illustrate the complexity that will arise when all of the mRNA decay pathways and their targets are considered collectively. Indeed, future advances will depend on elucidating the complicated, multifactorial webs of regulatory events that coordinate the half-lives of cellular mRNAs, depending on the stage of organismal development, the type of tissue and the surrounding environmental conditions. Genetic and biochemical approaches have identified the deadenylases, decapping enzymes and exonucleases that catalyse mRNA decay. Within the next several years, it is likely that most, if not all, endonucleases will have been catalogued and characterized. Sequence comparison has not been very successful in identifying endonucleases that act on mRNAs, thus their identification will require careful application of biochemical and molecular biological approaches. Identification of the targets and cleavage sites of these enzymes will be possible through the application of RNA sequencing. Together with improvements in computational approaches to RNA structure determinations, the knowledge gained from such studies will play a crucial part in defining the molecular code that directs particular transcripts to regulated decay processes and should also provide insights into the mechanisms that are responsible for generating many of the poorly characterized small RNAs.
Given the advent of high-throughput proteomic and sequencing technologies, it is also becoming possible to identify the constituents of individual mRNPs: RIP followed by sequencing (RIP-seq) can be used to deepsequence mRNAs that co-immunoprecipitate with a particular protein as well as ncRNAs that could regulate at least some of the mRNAs; and mass spectrometry can be used to identify proteins in these complexes and their post-translational modifications. After it has been established, it then becomes important to uncover how the sequences and structures of mRNAs -including their post-transcriptional modifications (consider, for example, the terminal U transferases that promote exosomemediated mRNA decay) -and their associated proteins and ncRNAs interact dynamically in response to signal transduction pathways to determine mRNA half-lives.
Integrating the many mRNA-specific regulatory pathways with those pathways that modulate the half-lives of multiple mRNAs will be a daunting task requiring sophisticated mathematical modelling. The complexity of such a task is compounded by the direct participation of nuclear receptors, indicating that mRNA half-lives could be regulated by cell environment, age and type. After understanding how mRNA decay is regulated by intracellular signal transduction at the single-cell level, it will become important to evaluate intracellular signal transduction-mediated regulation at the organ level. As an added caveat, although mRNAs largely function to produce proteins, there is growing support for the idea that they can also serve as sinks for regulatory proteins and antisense ncRNAs such as miRNAs by functioning as 'competing endogenous RNAs' (ceRNAs) 99 . This indicates that the regulation of mRNA decay may cast a very broad net and affect as of yet unappreciated cellular processes.
In the end, it is hoped that new insights into how mRNA decay is regulated will uncover new therapies to treat inherited and acquired diseases (BOX 5) . Developing such therapies is at the forefront of a number of biotechnology companies and academic laboratories.
Box 5 | RNA degradation and disease
Many diseases are due to the misregulation of mRNA decay (for a review, see REF. 53 ). For example, the level of the up-frameshift 3X (UPF3X) nonsense-mediated mRNA decay (NMD) factor is downregulated in patients with syndromic or non-syndromic intellectual disability who harbour mutations in UPF3X, which, as its name implies, is X-linked; as a consequence, the elevated level of the UPF3 NMD factor appears to compensate for the lack of UPF3X and lessens the disability 109, 110 . Another recently discovered example involves the von Hippel-Lindau (VHL) tumour suppressor that is inactivated in patients with VHL disease, an autosomally dominant cancer or clear-cell renal carcinoma. VHL was found to regulate the stability of the ARE-containing mRNA that encodes vascular endothelial growth factor (and, undoubtedly, other ARE-containing mRNAs) by targeting at least some isoforms of AUF1 for ubiquitylation and proteasome-mediated destruction 111 . It follows from this and many other studies that the targeted decay of particular mRNAs using, for example, small interfering RNAs (siRNAs) is at the forefront of developing therapies. Disease treatments based on siRNAs are challenging owing to the difficulties in delivering siRNAs to tissues and the inherent instability of siRNAs following delivery. In a recent promising approach, an arginine-glycine-aspartate tripeptide that mimics cell adhesion proteins and binds to integrins has been used to 'functionalize' siRNA nanoparticles. These siRNA nanoparticles target mRNA-encoding signal transducer and activator of transcription 1 (STAT1), which upregulates genes in response to signals by type I, type II or type III interferons 112 . The nanoparticles were found to be resistant to serum-mediated degradation, to be effectively taken up by tissues and to be effectively delivered to the joints of rheumatoid arthritic mice to alleviate disease 112 .
